April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Medical practices overview in wAMD in France
Author Affiliations & Notes
  • Benjamin Wolff
    Professor Sahel Dept, Fondation De Rothschild, Paris, France
  • Alexandre Bourhis
    Atlantique Polyclinic, Nantes, France
  • Pierre Loïc Cornut
    Val d'ouest Clinic, Ecully, France
  • Vincent Gualino
    Honoré Cave Clinic, Montauban, France
  • Hélène Massé
    Nantes Hospital, Nantes, France
  • Georges Souteyrand
    Nancy Hospital, Nancy, France
  • Maté Streho
    Explore Vision, Rueil Malmaison, France
  • Sarah Tick
    Professor Sahel Dept, XV XX Hospital, Paris, France
  • Jennyfer Zerbib
    Créteil Hospital, Créteil, France
  • Claire Chartier
    Novartis, Rueil Malmaison, France
  • Footnotes
    Commercial Relationships Benjamin Wolff, Novartis (C); Alexandre Bourhis, Novartis (C); Pierre Loïc Cornut, Novartis (C); Vincent Gualino, Allergan (C), Bayer (C), Novartis (C); Hélène Massé, Allergan (C), Bayer (C), Novartis (C); Georges Souteyrand, Bayer (C), Novartis (C); Maté Streho, Novartis (C); Sarah Tick, Bayer (C), Novartis (C); Jennyfer Zerbib, Novartis (C); Claire Chartier, Novartis (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3920. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Benjamin Wolff, Alexandre Bourhis, Pierre Loïc Cornut, Vincent Gualino, Hélène Massé, Georges Souteyrand, Maté Streho, Sarah Tick, Jennyfer Zerbib, Claire Chartier, ; Medical practices overview in wAMD in France. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3920.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: wAMD is a chronic disease mediated by intravitreal injections of the anti-vascular endothelial growth factor (VEGF) that primarily affects an older population (50 y.o and over). If a consensus exists in the induction phase of 3 injections of anti-VEGF, there is a gap for diagnostic and disease management among ophtalmologists to face healthcare organization. The objective of the research was to confirm this hypothesis and better understand practices.

Methods: Ipsos carried out a qualitative survey among 16 retinal specialists and 9 ophthalmologists from September 18th to October 22nd 2013. 15 telephone interviews and 4 face to face duos with 1 retinal specialist and 1 ophthalmologist were carried out. This qualitative survey allowed building a quantitative survey with 200 retinal specialists and ophthalmologists to assess practices in wAMD from screening to follow up. Qualitative survey highlighted practices to be explored in quantitative survey. Our hypothesis was that the different practices were less correlated to patient profiles than ophthalmologists’ profiles in terms of attitudes towards injections and OCT. Those practices were quantified and analysed throughout a national representative survey among ophthalmologists in France.

Results: Physicians’ roles in patient pathway were split between the ophthalmologist who diagnoses the wAMD and the retinal specialist who treats it. At the acute induction stage: treatment schedule was a routine with 3 monthly anti-VEGF injections. Retinal specialists unanimously emphasized the induction phase. Follow up practices were more inhomogeneous. Influencing factors on patients addressing, injection planning and overall organization were key points identified.

Conclusions: Anti-VEGF is the mainstay treatment in wAMD. The initial phase is a 3 monthly injections routine. This suvey aimed to analyse the differences still persisting in management before and after this initial treatment

Keywords: 688 retina • 465 clinical (human) or epidemiologic studies: systems/equipment/techniques  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×